Multicenter Study Reveals Improved Long-Term Success Rates With Stereotaxis Technology in Ventricular Tachycardia
“This study further supports the strength of the Niobe system in effectively finding and eliminating even the most difficult to treat arrhythmias,” said
The retrospective study reported on a total of 218 consecutive patients with ischemic cardiomyopathy and scar size greater than 60 cm2 undergoing VT ablation in multiple centers. Eighty patients were treated with manual ablation and 138 patients underwent ablation with the Niobe system. Substrate mapping and an ablation technique utilizing scar homogenization were performed, with the end point of elimination of all abnormal electrograms within and around the scar area. The density of mapping was higher (p<0.001) and the mean mapping time was lower (p<0.001) in the Niobe group when compared to the manual ablation group. Moreover, while acute success was achieved in 99.5% of all patients, at 15±6.8 month follow-up, 81.2% of patients in the Niobe group were VT recurrence free compared to 69% of the manual catheter patient group (p=0.037).
The core components of Stereotaxis’ systems have received regulatory clearance in
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in
STXS Company Contact:
Martin StammerChief Financial Officer 314-678-6155 STXS Investor Contact: Todd Kehrli/ Jim Byers MKR Group, Inc.323-468-2300 firstname.lastname@example.org